George Coleman, MD
Addiction Medicine · Raleigh, NCNPI 1801241104
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.
Across 19 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$82
- Indivior Inc.$75
- Vanda Pharmaceuticals Inc.$66
- Axsome Therapeutics, Inc.$45
- Lundbeck LLC$34
- Novo Nordisk$29
- plus $106 from 5 others
What the payments were for
- Food & beverage$437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $82 |
| Indivior Inc. | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 2 | $66 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Lundbeck LLC | 1 | $34 |
| Novo Nordisk | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Braeburn Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
How this compares
$437 in reported general payments places this provider in the 65th percentile of 42 addiction medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 62 | $8,805 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 11 | $5,289 |
| Gabapentin | 17 | $111 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Raleigh
- Christopher ThompsonRaleigh$71
- Robyn JordanRaleigh$58
- Bernard GottschalkWilmington$188K
- Hien NguyenApex$145K
- Gary LeonhardtGreenville$92K
- Emily Rayes-PrinceMonroe$69K
- Jonathan HallHendersonville$8K
- Barry WilliamsWinston-Salem$4K
- Johnny WilliamsGreenville$3K
- Heather ManosCharlotte$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.